[Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse events. Data from the Evaluation of Platelets IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial].
De Servi
S
S
Unità Operativa di Cardiologia, Ospedale Civile, Legnano, MI.
D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000601:surgery*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control; D011300:Preoperative Care; D015607:Stents / Q000009:adverse effects*; D013988:Ticlopidine / Q000627:therapeutic use*
D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine
Il pretrattamento con ticlopidina nello stent coronarico è associato a significativa riduzione di eventi avversi. Dati dal trial EPISTENT.